Constellation Pharmaceuticals, Inc. (CNST): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNST Stock Price Chart Interactive Chart >
CNST Price/Volume Stats
|Current price||$33.99||52-week high||$39.30|
|Prev. close||$33.97||52-week low||$17.00|
|Day high||$34.05||Avg. volume||940,325|
|50-day MA||$28.38||Dividend yield||N/A|
|200-day MA||$27.15||Market Cap||1.63B|
Constellation Pharmaceuticals, Inc. (CNST) Company Bio
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company’s lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors and/or hematological malignancies; and CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Most Popular Stories View All
CNST Latest News Stream
|Loading, please wait...|
CNST Latest Social Stream
View Full CNST Social Stream
Latest CNST News From Around the Web
Below are the latest news stories about Constellation Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNST as an investment opportunity.
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty PharmaPLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") for $34.
Should I Avoid Constellation Pharmaceuticals, Inc. (CNST)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Lifshitz Law Firm, P.C. Announces Investigation of ALTA, CAI, CNST, and IKNX
NEW YORK, NY / ACCESSWIRE / July 7, 2021 /Altabancorp (NasdaqCM:ALTA)Lifshitz Law Firm, P. announces investigation into possible breach of fiduciary duties in connection with the merger of ALTA with GBCI.
INVESTIGATION ALERT: Halper Sadeh LLP Investigates IKNX, MPB, JAX, CNST; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Lifshitz Law Firm, P.C. Announces Investigation of CNST, FFWM, SLCT, and GRA
NEW YORK, NY / ACCESSWIRE / July 2, 2021 / Lifshitz Law Firm, P.:Constellation Pharmaceuticals, Inc.
CNST Price Returns
Loading social stream, please wait...